Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice

Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, USA.
Circulation (Impact Factor: 14.43). 04/2010; 121(15):1746-55. DOI: 10.1161/CIRCULATIONAHA.109.924886
Source: PubMed


T cells play an important role during the immune response that accompanies atherosclerosis. To date, the role for interleukin (IL)-17A in atherogenesis is not well defined. Here, we tested the hypothesis that atherosclerosis-prone conditions induce the differentiation of IL-17A-producing T cells, which in turn promote atherosclerosis.
IL-17A was found to be elevated in the plasma and tissues of apolipoprotein E-deficient (Apoe(-/-)) mice. IL-17A-expressing T cells were significantly increased in the aortas, spleen, and lamina propria of aged Apoe(-/-) mice compared with age-matched C57BL/6 mice. IL-17A(+) T cells resided in both adventitia and aortas of aged Apoe(-/-) mice fed a chow diet. Elevated levels of IL-17A(+) T cells were also detected in the aortas of 21-week-old Apoe(-/-) mice fed a Western diet for 15 weeks. IL-17A(+) T cells were characterized as predominantly CD4(+) T helper 17 (Th17) cells and gammadelta(+) T cells. Blockade of IL-17A in Apoe(-/-) mice by use of adenovirus-produced IL-17 receptor A reduced plaque burden in Apoe(-/-) mice fed a Western diet for 15 weeks. In addition, the treatment diminished circulating IL-6 and granulocyte colony-stimulating factor levels and limited CXCL1 expression and macrophage content within the aortas. Conversely, IL-17A treatment of whole aorta isolated from Apoe(-/-) mice promoted aortic CXCL1 expression and monocyte adhesion in an ex vivo adhesion assay.
These results demonstrate that atherosclerosis-prone conditions induce the differentiation of IL-17A-producing T cells. IL-17A plays a proatherogenic inflammatory role during atherogenesis by promoting monocyte/macrophage recruitment into the aortic wall.

Download full-text


Available from: Anca D Dobrian, Feb 20, 2015
  • Source
    • "Several studies indicated that Th1 cells had a proatherogenic role since blocking Th1 polarization by pentoxifylline significantly attenuated atherosclerotic lesion development in experimental atherosclerosis mice model [3]. In addition, it has been reported that Th17 cells were also deeply involved in the development of atherosclerotic lesions [4], [5]. The up-regulation of Th17 response was observed in both local atherosclerotic plaque and circulating lymphocytes which accelerated atherosclerotic lesion formation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accumulating evidence indicates that both defects in Treg numbers and/or function as well as resistance of effector T cells to suppression may contribute to the development of human chronic inflammatory diseases. However, which mechanism involved in the progression of atherosclerosis remains unclear. In this study, we evaluated the production and function of CD4+ inflammatory and regulatory T cells in atherosclerosis-prone mice. We found that the hyperactivity and unresponsiveness to Treg-mediated suppression of inflammatory CD4+ T cells occurred in the progression of atherosclerosis, though Treg cells were present in very large numbers and fully functional. We further found that Gr-1+CD11b+ immature myeloid cells were significantly accumulated in atherosclerotic Apo E-/- mice, and they promoted resistance of inflammatory CD4+ T cells to Treg-mediated suppression in vitro and in vivo. we further confirmed that Gr-1+CD11b+ immature myeloid cells produced high level of interleukin 6 which was at least partially responsible for inducing unresponsiveness of inflammatory CD4+ T cells to suppression via activation of Jak/Stat signaling pathway. Taken together, these findings might provide new insights to explore potential targets for immune therapeutic intervention in atherosclerosis.
    PLoS ONE 09/2014; 9(9):e108620. DOI:10.1371/journal.pone.0108620 · 3.23 Impact Factor
  • Source
    • "IL-17A is a proinflammatory cytokine [12], highly produced in patients with chronic inflammatory International Journal of Inflammation diseases, such as RA, MS, and IBD [13] [14] [15]. IL-17A is also involved in atherosclerosis [16]; furthermore, in humans a positive correlation has also been found between circulating IL-17A levels and acute coronary syndrome [17] [18]. These findings have suggested that IL-17A might play a role in the cardiovascular risk associated with systemic immunological disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-17A (IL-17A), the most widely studied member of the IL-17 cytokine family, is a cytokine which emerged to be critical for host defense as well as in the pathogenesis of autoimmune disorders. Moreover, IL-17A is involved in the pathogenesis of cardiovascular diseases, such as atherosclerosis and acute coronary syndrome and in the cardiovascular risk associated with systemic immunological disorders. Consistent with this, we have recently shown that IL-17A increases human and murine platelet response to ADP. In this study we expanded our previous observation and we describe for the first time an in vivo prothrombotic effect of the cytokine. Our results show that IL-17A is synergic with a low FeCl3 concentration in inducing carotid thrombus in rats and suggest that the effect is likely related to a downregulation of CD39 vascular expression and hydrolyzing activity. Our findings indicate that IL-17A might be an important molecule at the interface between hemostasis and inflammation. “This paper is dedicated to the memory of Professor Alfredo Colonna”
    04/2014; 2014:247503. DOI:10.1155/2014/247503
  • Source
    • "Macrophages were the first well-described inflammatory participant in T2D as well as atherosclerosis, whose recruitment directly contributed to the systemic inflammatory status and plaque formation [24]. More recently, however, it is revealed that an elevation of Th1 and Th17 subsets [25, 26] accompanied by a significant decrease of regulatory T cells (Tregs) [27] may directly trigger the activation and infiltration of macrophage and thus systemic or local inflammation in the development of atherosclerosis and CHD [28]. However, the exact roles and underlying mechanisms of the Th subsets in CHD were far from being elucidated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Coronary atherosclerotic heart disease (CHD) is one of the major concerns in type 2 diabetes (T2D). The systemic chronic inflammation has been postulated to bridge the increased risk of cardiovascular disease and T2D. We formulated that increased peripheral proinflammatory T helper subsets contributed to the development of cardiovascular complications in diabetic patients. Methods: The frequencies of peripheral total CD4+ T helper cells, proinflammatory Th1, Th17, and Th22 subsets were determined by flow cytometry in diabetic patients with or without CHD (n = 42 and 67, resp.). Results: Both peripheral frequencies and total numbers of Th1, Th17, and Th22 cells were further increased in diabetic patients with CHD. Logistic regression and categorical cross-table analysis further confirmed that increased proinflammatory Th subsets, especially Th22, were independent risk factors of cardiovascular complication in diabetes. Elevated Th subsets also correlated with increased CRP levels and the atherogenic index of plasma. Moreover, Th1 frequency and Th22 numbers demonstrated remarkable potential in predicting CHD in diabetes. Conclusions: Increased peripheral proinflammatory T helper subsets act in concert and contribute to the increased prevalence of diabetic cardiovasculopathy. The recently identified Th22 cells might play an independent role in CHD and represent a novel proxy for cardiovascular risks in diabetes.
    Mediators of Inflammation 04/2014; 2014(1):596967. DOI:10.1155/2014/596967 · 3.24 Impact Factor
Show more